These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21045690)

  • 1. Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes.
    Olivier M; Taniere P
    Curr Opin Oncol; 2011 Jan; 23(1):88-92. PubMed ID: 21045690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
    Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
    Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection.
    Krawczak M; Smith-Sorensen B; Schmidtke J; Kakkar VV; Cooper DN; Hovig E
    Hum Mutat; 1995; 5(1):48-57. PubMed ID: 7728149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
    Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
    IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers.
    Chang YL; Wu CT; Lin SC; Hsiao CF; Jou YS; Lee YC
    Clin Cancer Res; 2007 Jan; 13(1):52-8. PubMed ID: 17200338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
    Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
    Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.
    Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M
    Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 and oesophageal cancer.
    Ferec C; Giroux MA; Audrezet MP; Robaszkiewicz M
    Pathol Biol (Paris); 1997 Dec; 45(10):871-5. PubMed ID: 9769951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline TP53 mutations and single nucleotide polymorphisms in children.
    Valva P; Becker P; Streitemberger P; Lombardi GM; Rey G; Guzman CA; Preciado MV
    Medicina (B Aires); 2009; 69(1 Pt 2):143-7. PubMed ID: 19414295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic analysis of deep-seated glioblastomas.
    Hayashi Y; Yamashita J; Watanabe T
    Cancer Genet Cytogenet; 2004 Aug; 153(1):64-8. PubMed ID: 15325097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives.
    de Moura Gallo CV; Azevedo E Silva Mendonça G; de Moraes E; Olivier M; Hainaut P
    Mutat Res; 2005 May; 589(3):192-207. PubMed ID: 15878142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.